Unprocessed U1 snRNAs as a biomarker of INTS11- and BRAT1-related neurodevelopmental disorders
Unprocessed RNA accumulation offers a measurable biomarker to identify disease severity in rare genetic neurological conditions and guide treatment decisions.
This multi-site study provides the first direct mechanistic evidence that BRAT1 mutations impair Integrator-mediated U1 snRNA processing, redefining BRAT1-associated neurological disease as an Integrator disorder. Nuclear accumulation of unprocessed U1 snRNAs emerged as a quantitative biomarker correlating with clinical severity, offering a new tool for variant interpretation and patient stratification in these severe rare neurodevelopmental conditions.
What the study was
- Study design
- Multi-patient biomarker validation study with zebrafish functional model
- Population
- Patients with biallelic INTS11 or BRAT1 variants presenting with severe neurodevelopmental disorders; matched fibroblast and lymphoblastoid cell lines
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Genome Medicine
Why it surfaced
First disclosure of BRAT1's functional role in RNA processing and first demonstration that U1 snRNA misprocessing severity predicts clinical outcome in BRAT1/INTS11 disorders. Multi-institutional cohort + zebrafish validation in Genome Medicine. Directly enables more precise variant classification for families receiving VUS-level BRAT1 diagnoses. Rare disease, no existing molecular biomarker — high unmet need. Score ≥ 8 qualifies as HIGH.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.